Crescent Diagnostics
Crescent Diagnostics have developed a new test for osteoporosis, the BQT which is superior to the gold standard test and creates a new $2bn pa market opportunity.
Our business is to provide bone fracture risk information which doctors can use to implement preventative measures in post-menopausal women. We intend to initially open a testing laboratory in Dublin, and subsequently place instruments in labs across the US and EU and charge a fee per test analysed. Our core competitive advantage is in the IP around the biomarker and the development of the proprietary algorithm which produces the test result.
Minimum Investment: €25,000
Capital Required: €700,000
For further information on this deal register as a HBAN investor here.
